Acamprosate works by restoring the balance between excitatory and calming chemical signals in the brain that chronic alcohol use disrupts. When someone drinks heavily for a long time, the brain adapts to alcohol’s presence by ramping up excitatory signaling. Once alcohol is removed, that overexcited state persists, driving cravings, anxiety, and the pull to drink again. Acamprosate quiets that excess excitatory activity, making it easier to stay abstinent.
What Alcohol Does to Brain Chemistry
To understand how acamprosate helps, it’s useful to know what heavy drinking does to two key signaling systems in the brain. Alcohol enhances calming signals (carried by a neurotransmitter called GABA) and suppresses excitatory signals (carried by glutamate). Over months or years of regular drinking, the brain compensates: it dials down GABA activity and ramps up glutamate activity to counterbalance alcohol’s effects.
When someone stops drinking, the compensatory changes don’t immediately reverse. The brain is left in a hyperexcitable state, with too much glutamate firing and not enough calming activity to counteract it. This imbalance is what fuels the restlessness, insomnia, anxiety, and intense cravings that make early sobriety so difficult. It can persist for weeks or months after the last drink, well beyond the acute withdrawal period.
How Acamprosate Targets Glutamate
Acamprosate’s primary action is on the glutamate system. It modulates a specific type of glutamate receptor called the NMDA receptor, which plays a central role in the hyperexcitability that follows chronic alcohol use. By dampening NMDA receptor activity, acamprosate reduces the flood of excitatory signaling that would otherwise keep the brain in overdrive.
It also appears to work through a second glutamate pathway. Acamprosate blocks a receptor called mGluR5, one of the metabotropic glutamate receptors that fine-tune how glutamate signals are processed. This dual action on both NMDA and mGluR5 receptors helps explain why the drug can reduce cravings and the neurological discomfort of early abstinence. Research published in the British Journal of Clinical Pharmacology also suggests acamprosate may prevent the kind of nerve cell damage that excessive glutamate activity can cause.
Effects on GABA and Dopamine
Acamprosate was originally thought to work primarily on GABA, the brain’s main calming neurotransmitter. That picture has evolved. Current evidence suggests its effect on GABA signaling is indirect, likely occurring through inhibition of a related receptor subtype rather than direct stimulation. The result is still a subtle boost to the brain’s calming signals, but it’s not the drug’s main mechanism.
There’s also an indirect effect on dopamine, the neurotransmitter tied to reward and motivation. Acamprosate may increase dopamine activity in the brain’s reward center through a chain of events involving both the mGluR5 and glycine receptor pathways. This could help normalize the blunted reward signaling that makes people in early recovery feel flat or unable to experience pleasure without alcohol.
How Well It Works
A large meta-analysis pooling 17 randomized controlled trials with over 4,000 participants found that acamprosate significantly improved abstinence rates at every time point measured. At six months, 36.1% of people taking acamprosate remained continuously abstinent compared to 23.4% on placebo. By 12 months, the overall difference in success rates between acamprosate and placebo was 13.3 percentage points, meaning roughly one in every eight people treated with acamprosate stayed sober specifically because of the medication.
Those numbers may sound modest, but in addiction treatment, where relapse rates are high across the board, a consistent and statistically significant edge is clinically meaningful. The effect also grew stronger over time: the relative benefit at 12 months was larger than at 3 or 6 months, suggesting acamprosate’s value increases the longer someone stays on it.
What Taking It Looks Like
The standard regimen is two 333 mg tablets taken three times a day, totaling about 2,000 mg daily. That dosing schedule, six pills spread across the day, is one of the practical challenges of the medication. It’s meant to be started after someone has already stopped drinking, and it’s designed to support abstinence rather than reduce drinking in people who are still actively consuming alcohol.
Acamprosate is not metabolized by the liver, which is a notable advantage for people with alcohol-related liver damage. The body excretes it through the kidneys unchanged. That kidney-dependent elimination does create one important limitation: people with moderate kidney impairment need a significantly reduced dose, and those with severe kidney impairment should not take it at all.
Side Effects and Interactions
Acamprosate is generally well tolerated. Gastrointestinal symptoms, particularly diarrhea, are the most commonly reported side effect. These tend to be mild and often improve over the first few weeks of treatment.
One of acamprosate’s advantages over other medications used for alcohol dependence is its low potential for drug interactions. Unlike disulfiram and benzodiazepines, which are involved in numerous pharmacological interactions, acamprosate has very few. It can be safely combined with naltrexone, the other widely prescribed medication for alcohol dependence, and it does not interact with alcohol itself, meaning a relapse episode won’t cause a dangerous reaction.
How It Differs From Other Alcohol Medications
Acamprosate occupies a distinct niche among alcohol dependence medications. Naltrexone works by blocking opioid receptors, reducing the pleasurable “buzz” from drinking so that alcohol feels less rewarding. Disulfiram takes a completely different approach: it causes an unpleasant physical reaction (nausea, flushing, rapid heartbeat) if you drink, acting as a deterrent.
Acamprosate does neither of those things. It doesn’t make drinking unpleasant and it doesn’t block alcohol’s effects. Instead, it addresses the neurochemical aftermath of chronic drinking, easing the brain back toward a normal baseline so that the internal pressure to drink diminishes over time. This makes it particularly suited for people who have already achieved initial sobriety and want neurological support to maintain it, rather than people trying to cut back while still drinking.